AR087803A1 - N-hidroxi-4-{2-[3-n,n-dimetilaminometil)benzofuran-2-ilcarbonilamino]etoxi}benzamida y esquema para administrarla - Google Patents
N-hidroxi-4-{2-[3-n,n-dimetilaminometil)benzofuran-2-ilcarbonilamino]etoxi}benzamida y esquema para administrarlaInfo
- Publication number
- AR087803A1 AR087803A1 ARP120103299A ARP120103299A AR087803A1 AR 087803 A1 AR087803 A1 AR 087803A1 AR P120103299 A ARP120103299 A AR P120103299A AR P120103299 A ARP120103299 A AR P120103299A AR 087803 A1 AR087803 A1 AR 087803A1
- Authority
- AR
- Argentina
- Prior art keywords
- benzofuran
- benzamide
- ilcarbonylamine
- dimethylaminome
- etoxi
- Prior art date
Links
- KXDAEFPNCMNJSK-UHFFFAOYSA-N benzene carboxamide Natural products NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 title 1
- 238000002512 chemotherapy Methods 0.000 abstract 2
- YXTKHLHCVFUPPT-YYFJYKOTSA-N (2s)-2-[[4-[(2-amino-5-formyl-4-oxo-1,6,7,8-tetrahydropteridin-6-yl)methylamino]benzoyl]amino]pentanedioic acid;(1r,2r)-1,2-dimethanidylcyclohexane;5-fluoro-1h-pyrimidine-2,4-dione;oxalic acid;platinum(2+) Chemical group [Pt+2].OC(=O)C(O)=O.[CH2-][C@@H]1CCCC[C@H]1[CH2-].FC1=CNC(=O)NC1=O.C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 YXTKHLHCVFUPPT-YYFJYKOTSA-N 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 238000001794 hormone therapy Methods 0.000 abstract 1
- 238000001959 radiotherapy Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 238000001356 surgical procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
- C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C07D307/84—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D307/85—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pathology (AREA)
- Radiology & Medical Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Furan Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
N-hidroxi-4-{2-[3-(N,N-dimetilaminometil)benzofuran-2-ilcarbonilamino]etoxi}benzamida de fórmula (1), o de una de sus sales de adición a un ácido o a una base farmacéuticamente aceptable, solo o en asociación con un tratamiento de cirugía, de quimioterapia, de hormonoterapia o con radioterapia para su utilización en el tratamiento del cáncer, caracterizada porque se administra durante 4 días consecutivos, estando seguido este periodo de 3 días consecutivos sin ninguna administración del compuesto de fórmula (1), con la salvedad de que el tratamiento de quimioterapia no es el FOLFOX.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161573585P | 2011-09-08 | 2011-09-08 | |
| FR1102727 | 2011-09-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR087803A1 true AR087803A1 (es) | 2014-04-16 |
Family
ID=47830027
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP120103299A AR087803A1 (es) | 2011-09-08 | 2012-09-07 | N-hidroxi-4-{2-[3-n,n-dimetilaminometil)benzofuran-2-ilcarbonilamino]etoxi}benzamida y esquema para administrarla |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US8883199B2 (es) |
| EP (1) | EP2753322B1 (es) |
| JP (1) | JP6014142B2 (es) |
| KR (1) | KR20140073521A (es) |
| CN (1) | CN103889409A (es) |
| AR (1) | AR087803A1 (es) |
| AU (2) | AU2012306122A1 (es) |
| CA (1) | CA2847011A1 (es) |
| HK (1) | HK1201150A1 (es) |
| MX (1) | MX2014002663A (es) |
| RU (1) | RU2600793C2 (es) |
| SG (2) | SG10201505619QA (es) |
| TW (1) | TWI544920B (es) |
| UA (1) | UA113634C2 (es) |
| UY (1) | UY34295A (es) |
| WO (1) | WO2013034863A1 (es) |
| ZA (1) | ZA201401710B (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004092115A2 (en) | 2003-04-07 | 2004-10-28 | Axys Pharmaceuticals Inc. | Hydroxamates as therapeutic agents |
| KR20120090100A (ko) * | 2006-12-26 | 2012-08-16 | 파마시클릭스, 인코포레이티드 | 병용 치료에 있어서 히스톤 디아세틸라제 억제제 이용 및 생체표지 감시 방법 |
| EP2993473A1 (en) * | 2007-01-30 | 2016-03-09 | Pharmacyclics, Inc. | Methods for determining cancer resistance to histone deacetylase inhibitors |
| US8603521B2 (en) | 2009-04-17 | 2013-12-10 | Pharmacyclics, Inc. | Formulations of histone deacetylase inhibitor and uses thereof |
| CN103917231B (zh) | 2011-09-13 | 2016-09-28 | 药品循环有限责任公司 | 组蛋白脱乙酰酶抑制剂与苯达莫司汀的联合制剂及其用途 |
| WO2015017812A1 (en) | 2013-08-02 | 2015-02-05 | Pharmacyclics, Inc. | Methods for the treatment of solid tumors |
| KR101684854B1 (ko) * | 2016-06-13 | 2016-12-09 | 아이오틴 주식회사 | 보호자 알림기능을 이용한 휴대용 스마트약통 및 이를 포함하는 복용시간 알림시스템 |
| CN114146181B (zh) * | 2021-10-29 | 2022-09-09 | 徐诺药业(南京)有限公司 | 含Pan-HDAC和免疫检查点抑制剂的组合及应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1489078E (pt) * | 2002-03-28 | 2010-02-24 | Mitsubishi Tanabe Pharma Corp | Derivados de benzofurano |
| JP2005530734A (ja) * | 2002-04-15 | 2005-10-13 | スローン − ケッタリング インスティチュート フォー キャンサー リサーチ | 癌の処置のための併用療法 |
| WO2004092115A2 (en) * | 2003-04-07 | 2004-10-28 | Axys Pharmaceuticals Inc. | Hydroxamates as therapeutic agents |
| KR20080008367A (ko) * | 2005-04-21 | 2008-01-23 | 알자 코포레이션 | 리포좀에 봉입된 독소루비신으로 진행성 난소암을 치료하는방법 |
-
2012
- 2012-08-28 UY UY0001034295A patent/UY34295A/es not_active Application Discontinuation
- 2012-09-06 US US13/605,116 patent/US8883199B2/en active Active
- 2012-09-06 TW TW101132604A patent/TWI544920B/zh not_active IP Right Cessation
- 2012-09-07 CN CN201280041854.3A patent/CN103889409A/zh active Pending
- 2012-09-07 MX MX2014002663A patent/MX2014002663A/es unknown
- 2012-09-07 UA UAA201403500A patent/UA113634C2/uk unknown
- 2012-09-07 CA CA2847011A patent/CA2847011A1/fr not_active Abandoned
- 2012-09-07 HK HK14112851.7A patent/HK1201150A1/xx unknown
- 2012-09-07 AU AU2012306122A patent/AU2012306122A1/en not_active Abandoned
- 2012-09-07 EP EP12769146.7A patent/EP2753322B1/fr active Active
- 2012-09-07 JP JP2014529056A patent/JP6014142B2/ja active Active
- 2012-09-07 KR KR1020147009191A patent/KR20140073521A/ko not_active Ceased
- 2012-09-07 WO PCT/FR2012/052004 patent/WO2013034863A1/fr not_active Ceased
- 2012-09-07 RU RU2014113399/15A patent/RU2600793C2/ru not_active IP Right Cessation
- 2012-09-07 SG SG10201505619QA patent/SG10201505619QA/en unknown
- 2012-09-07 AR ARP120103299A patent/AR087803A1/es unknown
- 2012-09-07 SG SG11201400120UA patent/SG11201400120UA/en unknown
-
2014
- 2014-03-07 ZA ZA2014/01710A patent/ZA201401710B/en unknown
- 2014-10-09 US US14/510,369 patent/US20150024040A1/en not_active Abandoned
-
2016
- 2016-04-22 AU AU2016202594A patent/AU2016202594B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| TWI544920B (zh) | 2016-08-11 |
| CN103889409A (zh) | 2014-06-25 |
| SG10201505619QA (en) | 2015-08-28 |
| MX2014002663A (es) | 2014-08-29 |
| UA113634C2 (uk) | 2017-02-27 |
| RU2014113399A (ru) | 2015-10-20 |
| CA2847011A1 (fr) | 2013-03-14 |
| AU2016202594B2 (en) | 2017-09-14 |
| HK1201150A1 (en) | 2015-08-28 |
| SG11201400120UA (en) | 2014-09-26 |
| JP2014526457A (ja) | 2014-10-06 |
| WO2013034863A1 (fr) | 2013-03-14 |
| AU2016202594A1 (en) | 2016-05-19 |
| AU2012306122A1 (en) | 2014-03-13 |
| RU2600793C2 (ru) | 2016-10-27 |
| EP2753322B1 (fr) | 2016-08-03 |
| JP6014142B2 (ja) | 2016-10-25 |
| NZ622112A (en) | 2016-07-29 |
| TW201313228A (zh) | 2013-04-01 |
| UY34295A (es) | 2013-04-30 |
| US20130064880A1 (en) | 2013-03-14 |
| ZA201401710B (en) | 2015-01-28 |
| US8883199B2 (en) | 2014-11-11 |
| EP2753322A1 (fr) | 2014-07-16 |
| KR20140073521A (ko) | 2014-06-16 |
| US20150024040A1 (en) | 2015-01-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR087803A1 (es) | N-hidroxi-4-{2-[3-n,n-dimetilaminometil)benzofuran-2-ilcarbonilamino]etoxi}benzamida y esquema para administrarla | |
| CY1124882T1 (el) | Αναλογα 1,4-διϋποκατεστημενης πυριδαζινης και μεθοδοι για την θεραπευτικη αγωγη καταστασεων συναφων με ανεπαρκεια smn | |
| MX383686B (es) | Derivados de piridazina 1,4-disustituida, y su uso para el tratamiento de afecciones relacionadas con la deficiencia de smn. | |
| AR078588A1 (es) | Combinaciones de un inhibidor de pi3k y un inhibidor de mek | |
| CR20150628A (es) | Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades | |
| ECSP099436A (es) | Acilaminopirazoles como inhibidores de fgfr | |
| MX2015006039A (es) | Derivados de pirimidin-2, 4-diamina para el tratamiento de cancer. | |
| CL2012001911A1 (es) | Compuestos derivados de fumarato; composicion farmaceutica que los comprende; y su uso en el tratamiento de una enfermedad inflamatoria o neurodegenerativa. | |
| AR087668A1 (es) | Derivados de oxazina y su uso en el tratamiento de enfermedades | |
| ES2691742T3 (es) | Tratamiento de cánceres utilizando moduladores de isoformas de PI3 cinasa | |
| NI200900184A (es) | Uso de compuestos inhibidores de quinaxolina de pi3k-alfa para el tratamiento del cáncer. | |
| PH12014501277A1 (en) | Kinase inhibitors | |
| CO6680645A2 (es) | Inhibidores de oxadiazol de la producción de leucotrieno | |
| AR086356A1 (es) | Combinacion farmaceutica para usar en el tratamiento de pacientes que padecen diabetes de tipo 2 | |
| AR087995A1 (es) | Derivados de n-(4-{[6,7-bis(metiloxi)quinolin-4-il]oxi}fenil)-n-(4-fluorofenil)ciclopropan-1,1-dicarboxamida | |
| MY207696A (en) | 2,3-dihydro-1h-pyrrolizine-7-formamide derivative and application thereof | |
| MX2020005736A (es) | Derivados de glutarimida, uso de los mismos, composicion farmaceutica basada en los mismos y metodos para producir derivados de glutarimida. | |
| MX2017003780A (es) | Composicion farmaceutica para tratar colitis ulcerativa. | |
| CR10850A (es) | Uso de derivados de acido de piranona sustituidos para el tratamiento del sindrome metabolico | |
| MY167216A (en) | Kinase inhibitors | |
| AR083575A1 (es) | Aminopirazoles para inhibir la proteinquinasa chk1 | |
| MX2021015447A (es) | Métodos de tratamiento del cáncer dirigidos a tumores fríos. | |
| AR080204A1 (es) | Procesos para preparar ciclopropilamidas e intermedios asociados con estas | |
| ES2530755T3 (es) | Terapia de combinación para el tratamiento del cáncer | |
| AR088287A1 (es) | Agente terapeutico y agente preventivo para la enfermedad desmielinizante |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |